CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Janssen Pharmaceutica N.V. v. Xellia Pharmaceuticals ApS

1:16-cv-00554

Overview

Case Number 1:16-cv-00554
Filing Date 2016-06-29
Status Terminated
Termination Date 2016-12-22
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Xellia Pharmaceuticals ApS NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Janssen Pharmaceutica N.V. NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Brian P. Egan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9454

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2016-04-04
1:16-cv-00224

Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6407079
Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
Filed: 1988-10-31
Issued: 2002-06-18
Expired (Term Ended)
Expires: 2008-10-31

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 8 STIPULATION TO EXTEND TIME for defendant to move, answer, or otherwise respond to the Complaint to December 19, 2016 filed by Janssen Pharmaceu...
Entry #β€” • 2016-09-30
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for defendant to move, answer, or otherwise respond to the Complaint to December 19, 2016 - filed by Janssen Pharmaceutica N.V.. (Blu...
Entry #8 • 2016-09-28 Document →

Docket Entries

(19 total)
Pleading / Complaint

COMPLAINT filed against Xellia Pharmaceuticals ApS - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1956293.) - filed by Janssen Pharmaceutica N.V.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(sar) (Entered: 06/30/2016)

Entry #1 • 2016-06-29
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 06/30/2016)

Entry #2 • 2016-06-29
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/24/2016. Date of Expiration of Patent: 6/18/2019.Thirty Month Stay Deadline: 11/24/2018. (sar) (Entered: 06/30/2016)

Entry #3 • 2016-06-29
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,407,079 B1;. (sar) (Entered: 06/30/2016)

Entry #4 • 2016-06-29
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceutica N.V. filed by Janssen Pharmaceutica N.V.. (sar) (Entered: 06/30/2016)

Entry #5 • 2016-06-29
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc